[Pharmacotherapy of patients with dementia].
Dementing illnesses present among the most frequent and most consequential psychiatric disorders in old age. They thus constitute a particular challenge for science politics and society as a whole. Knowledge about multifactorial etiological and pathological factors is still rather limited. By way of stratified diagnostic procedures various dementia disorders can be differentiated rather reliably. Anti-dementia drugs can enhance cognitive performance and temporarily slow down the progress of the most frequently occurring dementias (Alzheimer-dementia, vascular dementia). In the treatment of behavioral symptoms in dementia newly developed psychopharmological agents are of particular relevance. They constitute an important element of a multi-modal therapeutic strategy.
Hirsch
R D
RD
Abteilung für Gerontopsychiatrie und Gerontopsychiatrisches Zentrum, Rheinische Kliniken Bonn. r.d.hirsch@t-online.de
D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000191:economics; D003365:Costs and Cost Analysis; D003430:Cross-Sectional Studies; D016527:Drug Costs / Q000706:statistics & numerical data; D005858:Germany; D006801:Humans; D009313:National Health Programs / Q000191:economics; D018697:Nootropic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D010348:Patient Care Team / Q000191:economics; D011157:Population Dynamics; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents; D011619:Psychotropic Drugs